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Subcutaneous panniculitis-like T-cell lymphoma (SPT-
CL) is a rare type of cutaneous lymphoma accounting 
for less than 1% of all cutaneous lymphomas. SPTCL is 
characterized by the infiltration of neoplastic cytotoxic T 
cells into subcutaneous tissues, which makes it resemble 
lobular panniculitis. Haemophagocytic syndrome (HPS)/
haemophagocytic lymphohistiocytosis (HLH) is someti-
mes associated with SPTCLs, occurring in approximately 
17% of cases (1). On the other hand, visceral involvement 
is rarely observed in patients with SPTCL (1). We report 
here a case of a patient with SPTCL who developed bone 
marrow and lung involvement.
CASE REPORT
An 82-year-old Japanese man presented with a 6-month history 
of intermittent fever, non-productive cough, weight loss of 8 kg, 
and recurrent, multiple and painless subcutaneous nodules and 
plaques. Because plaques and high-grade fever were intractable 
despite oral prednisolone, 20–30 mg/day, the patient was referred 
to our hospital.
Physical examination revealed plaques, which ranged from 5 to 
20 mm in diameter, on the face, neck, upper chest and upper limbs 
(Fig. 1a, b). Laboratory investigations revealed pancytopaenia 
(white blood cell count 2.5×109/l (normal range 4.0–9.0 × 109/l); 
red blood cell count 2,910 × 109/l (4,270–5,700 × 109/l); platelet 
count 67 × 109/l (150–350 × 109/l)) with prolonged erythrocyte 
sedimentation rate (81 mm/h), and elevated serum levels of C-
reactive protein (6.03 mg/dl), lactate dehydrogenase (441 U/l), 
ferritin (641.9 ng/ml) and soluble interleukin-2 receptors (sIL-2R) 
(630 U/ml). Biopsy of the subcutaneous nodule in the left upper 
limb at the onset of the disease demonstrated lobular panniculitis 
(Fig. 1c) with infiltrating atypical lymphoid cells with pleomor­
phic nuclei (Fig. 1d). Focal rimming of adipocytes by the atypical 
cells, karyorrhexis and foamy histiocytes were also observed (Fig. 
1d). Immunohistochemistry showed that the cells rimming the 
adipocytes were positive for CD3, CD8 (Fig. 1e), T-cell intracel-
lular antigen­1 (Fig. 1h) and T­cell receptor (TCR)­βF1 (Fig. 1g), 
and negative for CD4 (Fig. 1f), CD20 (Fig. 1i), CD30, CD56 and 
TCRγδ (Fig. 1j). TCR­β gene clonal rearrangement was detected 
by PCR analysis from 2 identical samples of plaques. Bone marrow 
aspiration smears showed that 8.4% of total cells were atypical 
large lymphoid cells with enlarged and irregular nuclei. Bone 
marrow biopsy revealed moderate hypoplastic bone marrow tissue 
with infiltration of lymphoid cells expressing CD8 in the stromal 
layer of bone marrow tissue, but without haemophagocytosis (Fig. 
S1a, b1). A chest X-ray revealed bilateral patch areas of conso-
lidation in the middle-lower lung lobes (Fig. S1c1), which were 
confirmed as peribronchial infiltration on computed tomography. 
Culture of bronchoalveolar lavage fluid, plasma cytomegalovirus 
pp56, plasma Epstein­Barr virus DNA and interferon­γ release 
assays for tuberculosis were all negative, and the serum level 
of β­D­glucan was normal. Transbronchial lung biopsy showed 
perialveolar infiltration of predominant CD8+ T cells (Fig. S1d, 
e1). Accordingly, we diagnosed the patient as SPTCL with bone 
marrow and lung involvement.
After the first course of CHOP chemotherapy (cyclophosphami-
de 375 mg/m2, doxorubicin 50 mg/m2 and vincristine 1.4 mg/m2 at 
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Fig. 1. Clinical and pathological findings. (a) Plaques around the eyes, and 
(b) on the neck, upper chest, and upper limbs. Haematoxylin and eosin-stained 
biopsy specimens of the subcutaneous nodule in the left upper limb showed 
(c) lobular panniculitis (original magnification ×2) and (d) focal rimming of 
adipocytes by infiltrating atypical lymphoid cells with pleomorphic nuclei and foamy 
histiocytes (original magnification ×400). Immunohistochemistry were performed 
for (e) CD8, (f) CD4, (g) TCRβF1, (h) T-cell intracellular antigen-1, (i) CD20 and 
(j) TCRγδ. (Diaminobenzidine and haematoxylin, original magnification×400).
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day 1; prednisolone 100 mg for days 1–5), the symptoms resolved 
completely within 2 weeks. A total of 6 monthly courses of CHOP 
were completed, and prednisolone was tapered. Two months later, 
a relapse occurred, with plaques, pulmonary consolidation and 
fever despite 7.5 mg/day prednisolone. Administration of oral 
etoposide (50 mg daily for 3 weeks followed by a rest period of 
one week) as the second-line chemotherapy with increased dosage 
of prednisolone to 20 mg/day led to clinical remission again and 
prednisolone was tapered gradually and stopped. The treatment 
has completely suppressed recurrences for 30 months.
DISCUSSION
SPTCL was first described by Gonzalez et al. (2) in 1991 
as an uncommon form of cutaneous lymphoma with 
primary involvement of adipose tissue. Previously, the 
disease was thought to consist of an α/β TCR phenotype 
and a γ/δ TCR phenotype. Because γ/δ TCR phenotype 
have a more aggressive clinical course frequently ac-
companied by extracutaneous involvement and HPS 
than α/β TCR phenotype, the World Health Organization 
­ European Organisation for Research and Treatment of 
Cancer (WHO­EORTCC) classification of 2005 defines 
SPTCLs as those cases with an α/β TCR phenotype, and 
established a new category of primary cutaneous γ/δ 
T­cell lymphoma (CGD­TCL) (3). It was reported that 
there was no case with visceral involvement out of 63 
cases of SPTCL with an α/β TCR phenotype (1). To our 
knowledge, only 7 cases of SPTCL with extracutaneous 
involvement have been reported (4–8) (Table SI1). The af-
fected sites included bone marrow in 4 cases (5, 6); breast 
in 2 cases (4, 7); and liver (7), spleen (7) and mesenteric 
fat (8) in one case each. Only one case had multiple sites 
of extracutaneous involvement in addition to our case (7).
At present, a standard treatment protocol for SPTCL, 
especially for cases with visceral involvement, has not 
been established because of the rarity of the disease. A 
wide variety of treatment modalities have been reported, 
including corticosteroids, immunosuppressive agents, 
combination chemotherapy/radiotherapy, and bone 
marrow transplantation (1, 9, 10). Anthracycline-based 
regimes, such as CHOP therapy, were commonly used 
(9). Because almost all cases with SPTCLs present in-
dolent clinical courses, prednisolone or cyclosporine A 
monotherapy might be sufficient, as reported recently 
(7, 11, 12). Five cases with extracutaneous involvement 
were treated with combination chemotherapy including 
CHOP therapy (4–6, 8), while 2 cases were treated with 
cyclosporine A monotherapy (5, 7) (Table SI1). Even 
in cases treated with combination chemotherapies, 4 
cases were refractory to the first­line chemotherapies, 
experienced recurrence or died within 2 months after 
diagnosis (4–6, 8). Prolonged etoposide monotherapy 
resulted in long-term remission in our case following 
a relapse episode after CHOP therapy, while 3 cases 
were previously reported to experience recurrence after 
combination chemotherapies including etoposide (5, 6, 
8). Chronic daily oral low-dose etoposide therapy is re-
portedly effective in refractory lymphoma (13). Because 
the therapy is available on an outpatient basis with mild 
adverse events compared with combination chemo-
therapies, administration of etoposide is also useful and 
effective in elderly patients with refractory lymphoma 
(14). The current case is the first reported case of SPTCL 
with multiple extracutaneous involvement treated with 
etoposide monotherapy. This case indicates that etopo-
side might be an effective and safe drug to treat SPTCL 
patients with visceral involvement.
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